The Drug Pricing Summit Pharma Wasn't Invited To
Executive Summary
Does the Trump-Cummings confab mean that drug makers are doomed to price negotiations in Medicare Part D? (Answer: Almost certainly not, but this is Trump we're talking about.)
You may also be interested in...
Reducing Patents Gets Attention From House Freedom Caucus At Pricing Hearing
House Oversight Committee Ranking Member Jim Jordan suggests that Congress may need to re-evaluate the length of pharma patents and FDA exclusivities.
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump
The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.